Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Christopher J. Shepherd"'
Autor:
Michelle Morrow, Deborah J Wong, Maxwell J Kroloff, Josefin-Beate Holz, Omer Stern, Christopher J Shepherd, Louis Kayitalire
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 10 (2022)
Anaplastic thyroid cancer represents a rare, highly aggressive form of thyroid cancer with a poor prognosis and an overall survival ranging from 5 to 12 months. Unfortunately, treatment options remain limited, even for patients with a targetable driv
Externí odkaz:
https://doaj.org/article/a307d489f0144259ba45d1a43310d56f
Autor:
Timothy A. Yap, Patricia M. LoRusso, Deborah J. Wong, Siwen Hu-Lieskovan, Kyriakos P. Papadopoulos, Josefin-Beate Holz, Urszula Grabowska, Cristian Gradinaru, Kin-Mei Leung, Sylwia Marshall, Claire S. Reader, Roslin Russell, Richard C.A. Sainson, Claire J. Seal, Christopher J. Shepherd, Fiona Germaschewski, Daniel Gliddon, Omer Stern, Lesley Young, Neil Brewis, Louis Kayitalire, Michelle Morrow
Publikováno v:
Clinical Cancer Research. 29:888-898
Purpose:This phase 1 study (NCT03440437) evaluated the safety, tolerability, pharmacokinetics (PK), and activity of FS118, a bispecific antibody–targeting LAG-3 and PD-L1, in patients with advanced cancer resistant to anti–PD-(L)1 therapy.Patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9870f3d61f3370620b11f3584de2d6c4
https://doi.org/10.1158/1078-0432.ccr-22-1449
https://doi.org/10.1158/1078-0432.ccr-22-1449
Autor:
Michelle Morrow, Louis Kayitalire, Neil Brewis, Lesley Young, Omer Stern, Daniel Gliddon, Fiona Germaschewski, Christopher J. Shepherd, Claire J. Seal, Richard C.A. Sainson, Roslin Russell, Claire S. Reader, Sylwia Marshall, Kin-Mei Leung, Cristian Gradinaru, Urszula Grabowska, Josefin-Beate Holz, Kyriakos P. Papadopoulos, Siwen Hu-Lieskovan, Deborah J. Wong, Patricia M. LoRusso, Timothy A. Yap
Supplementary Table S1: Representativeness of Study Participants.Supplementary Table S2: Immunogenicity in patients treated with FS118.Supplementary Table S3: PK of FS118 by Dose Level.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27e7c2e048ad7d481d58db7e5f5c9dae
https://doi.org/10.1158/1078-0432.22489940
https://doi.org/10.1158/1078-0432.22489940
Autor:
Michelle Morrow, Louis Kayitalire, Neil Brewis, Lesley Young, Omer Stern, Daniel Gliddon, Fiona Germaschewski, Christopher J. Shepherd, Claire J. Seal, Richard C.A. Sainson, Roslin Russell, Claire S. Reader, Sylwia Marshall, Kin-Mei Leung, Cristian Gradinaru, Urszula Grabowska, Josefin-Beate Holz, Kyriakos P. Papadopoulos, Siwen Hu-Lieskovan, Deborah J. Wong, Patricia M. LoRusso, Timothy A. Yap
Supplementary information
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18b184e3f77517649b8130a606ef0a05
https://doi.org/10.1158/1078-0432.22489943
https://doi.org/10.1158/1078-0432.22489943
Autor:
Michelle Morrow, Louis Kayitalire, Neil Brewis, Lesley Young, Omer Stern, Daniel Gliddon, Fiona Germaschewski, Christopher J. Shepherd, Claire J. Seal, Richard C.A. Sainson, Roslin Russell, Claire S. Reader, Sylwia Marshall, Kin-Mei Leung, Cristian Gradinaru, Urszula Grabowska, Josefin-Beate Holz, Kyriakos P. Papadopoulos, Siwen Hu-Lieskovan, Deborah J. Wong, Patricia M. LoRusso, Timothy A. Yap
Supplementary Figure S1: Study design for the evaluation of FS118 in subjects with advanced solid tumors whoprogressed on or after prior PD-(L)1 therapy.Supplementary Figure S2: Time on FS118 treatment in patients with primary or acquired resistance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67b19bd1e4fc2bc411e31a1ea30e2ba5
https://doi.org/10.1158/1078-0432.22489946.v1
https://doi.org/10.1158/1078-0432.22489946.v1
Autor:
Michelle Morrow, Louis Kayitalire, Neil Brewis, Lesley Young, Omer Stern, Daniel Gliddon, Fiona Germaschewski, Christopher J. Shepherd, Claire J. Seal, Richard C.A. Sainson, Roslin Russell, Claire S. Reader, Sylwia Marshall, Kin-Mei Leung, Cristian Gradinaru, Urszula Grabowska, Josefin-Beate Holz, Kyriakos P. Papadopoulos, Siwen Hu-Lieskovan, Deborah J. Wong, Patricia M. LoRusso, Timothy A. Yap
Purpose:This phase 1 study (NCT03440437) evaluated the safety, tolerability, pharmacokinetics (PK), and activity of FS118, a bispecific antibody–targeting LAG-3 and PD-L1, in patients with advanced cancer resistant to anti–PD-(L)1 therapy.Patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b08ea5484c59f0d44d3a336fb85f05b3
https://doi.org/10.1158/1078-0432.c.6533066
https://doi.org/10.1158/1078-0432.c.6533066
Autor:
Maxwell J Kroloff, Josefin-Beate Holz, Omer Stern, Christopher J Shepherd, Michelle Morrow, Louis Kayitalire, Deborah J Wong
Publikováno v:
Journal for immunotherapy of cancer, vol 10, iss 10
Anaplastic thyroid cancer represents a rare, highly aggressive form of thyroid cancer with a poor prognosis and an overall survival ranging from 5 to 12 months. Unfortunately, treatment options remain limited, even for patients with a targetable driv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2540dcac4ccd09aaa3f7bb1023fbadc
https://doi.org/10.1136/jitc-2022-005225
https://doi.org/10.1136/jitc-2022-005225
Autor:
Antonia Perelló, Shah-Jalal Sarker, Isabel Ruiz, Andreas Makris, Elisabeth Oelmann, Cheryl Lawrence, A.M. Brunt, Anne Kendall, Joohyuk Sohn, Atiyyah Moosa, Keun Seok Lee, Gia Nemsadze, Marta Ferreira, Julien Grenier, Stephen Chan, Javier Cortes, Patricia Marosics, Michael Schenker, Peter Schmid, Catherine Harper-Wynne, Christopher J. Shepherd, John Conibear, Aaron Prendergast, Sherko Kuemmel, Matthias Zaiss, Kelly Mousa, Carike Coetzee, Janet E. Brown, Károly Máhr, Sidharth Dubey, Hartmut Kristeleit, Cristina Saura
Publikováno v:
JAMA Oncol
Importance Randomized clinical trials have demonstrated a substantial benefit of adding everolimus to endocrine therapy. Everolimus inhibits the mammalian target of rapamycin complex 1 (mTORC1) complex but not mTORC2, which can set off an activating
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c8d54221b1897791291965de5b98f83
https://eprints.whiterose.ac.uk/145642/33/jamaoncology_schmid_2019_oi_190056.pdf
https://eprints.whiterose.ac.uk/145642/33/jamaoncology_schmid_2019_oi_190056.pdf
Autor:
Anil K. Sood, Pamela T. Soliman, Robert L. Coleman, Christine Samuel, Rochelle A Williams, Wolfram Brugger, Elizabeth Janet Pease, Vicente Valero, Charles F Levenback, Larissa A. Meyer, Sadia Saleem, Stacy L. Moulder, Anna Marie Rodriguez, Michael Frumovitz, Annies Cyriac, Shannon N. Westin, Christopher J. Shepherd, Jennifer K. Litton, Gordon B. Mills, Laverne Engerman
Publikováno v:
Journal of Clinical Oncology. 36:5504-5504
5504Background: We sought to determine the recommended phase II dose (RP2D) of olaparib (O) and vistusertib (V) and evaluate molecular markers of response. Methods:Two oral schedules for V were exp...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f9ebcad48d8ef4a116d6e7bcbeb031b6
https://doi.org/10.1200/jco.2018.36.15_suppl.5504
https://doi.org/10.1200/jco.2018.36.15_suppl.5504